Heart attack stem cell therapy under Long-Term safety watch
NCT ID NCT07400458
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 100 people who received Hearticellgram-AMI, a stem cell treatment for acute heart attacks, to see if any serious side effects appear years later. Researchers are watching for death, new cancers, or immune reactions. The goal is to confirm the treatment's long-term safety after it was already approved.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hearticellgram-AMI (a cell therapy made from stem cells)
What this could lead to
If this study shows the treatment is safe over many years, it could support its continued use for heart attack recovery.
What could go wrong
This is a long-term safety follow-up, not a test of effectiveness. The treatment is already approved, but rare side effects may still emerge. The study is small (100 people) and observational, so results may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYOCARDIAL INFARCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
KIMHYUNSOO Clinic
RECRUITINGSeoul, Gangnam, 06017, South Korea
Contact Phone: •••-•••-••••